Effect of histone deacetylase and DNA methyltransferase inhibitors on the expression of the androgen receptor gene in androgen-independent prostate cancer cell lines

Fialova,Barbora; Smesny Trtkova,Katerina; Paskova,Lenka; Langova,Katerina; Kolar,Zdenek

doi:10.3892/or.2013.2344

Effect of histone deacetylase and DNA methyltransferase inhibitors on the expression of the androgen receptor gene in androgen-independent prostate cancer cell lines

Authors:
- Barbora Fialova
- Katerina Smesny Trtkova
- Lenka Paskova
- Katerina Langova
- Zdenek Kolar
View Affiliations

Affiliations: Laboratory of Molecular Pathology, Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 775 15 Olomouc, Czech Republic, Department of Medical Biophysics, Faculty of Medicine and Dentistry, Palacky University Olomouc, 775 15 Olomouc, Czech Republic
Published online on: March 13, 2013 https://doi.org/10.3892/or.2013.2344
Pages: 2039-2045

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Androgen receptor (AR) expression in prostate cancer (CaP) cells varies due to the multiple changes including epigenetic modifications such as DNA methylation and histone deacetylation. DNA methyltransferase and histone deacetylase inhibitors are promising for the treatment of CaP. The aim of our study was to analyze the 5-aza-2'-deoxycytidine (Aza‑dC) and sodium butyrate (NaB) effects on CaP cells with modified AR gene expression. The androgen-independent human prostate cancer cell lines PC3 (lacking a functional AR) and DU145 (strongly limited expression due to methylations in the AR gene) were used. PCR of bisulfite-modified DNA and RT-PCR with bisulfite-sequencing were used for AR gene analysis of DU145 and PC3 cells following their treatment with Aza-dC and/or NaB. Re-acetylated histones around the AR gene were detected by conventional PCR of immunoprecipitated DNA obtained from treated cells. In both cell lines without the AR expression, the combined treatment was followed with significant decrease of cell viability. The co-treatment of DU145 cells caused site-specific demethylation in the AR promoter region followed by gene re-expression and increased acetylation in histones H3 and H4. The co-treatment with Aza-dC and NaB was the most effective in demethylation and re-expression of the AR gene. In the AR gene promoter, the location and density of demethylated CpGs indicated the existence of distinct promoter hot spot that could be a target of AR gene inactivation therapy of CaP patients during androgen deprivation.

View Figures

View References

1	Knudsen K and Kelly WK: Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer. Expert Rev Endocrinol Metab. 6:483–493. 2011. View Article : Google Scholar : PubMed/NCBI
2	Gao F, Yang M, Luo L and Wu XH: Local insulin-like growth factor-I of ventral prostate was upregulated during long-term castration and may function through the autocrine system. Prostate Cancer Prostatic Dis. 14:136–142. 2011. View Article : Google Scholar
3	Culig Z and Puhr M: Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol. 360:52–58. 2012. View Article : Google Scholar : PubMed/NCBI
4	Mohler JL, Gregory CW, Ford OH III, Kim D, Weaver CM, Petrusz P, Wilson EM and French FS: The androgen axis in recurrent prostate cancer. Clin Cancer Res. 10:440–448. 2004. View Article : Google Scholar : PubMed/NCBI
5	Mohler JL: Castration-recurrent prostate cancer is not androgen-independent. Adv Exp Med Biol. 617:223–234. 2008. View Article : Google Scholar : PubMed/NCBI
6	Scher HI and Sawyers CL: Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 23:8253–8261. 2005. View Article : Google Scholar : PubMed/NCBI
7	Imamura T: Epigenetic setting for long-term expression of estrogen receptor α and androgen receptor in cells. Horm Behav. 59:345–352. 2011.PubMed/NCBI
8	Esteller M: Epigenetics in cancer. N Engl J Med. 358:1148–1159. 2008. View Article : Google Scholar
9	Gao L and Alumkal J: Epigenetic regulation of androgen receptor signaling in prostate cancer. Epigenetics. 5:100–104. 2010. View Article : Google Scholar : PubMed/NCBI
10	Martinez-Arguelles DB and Papadopoulos V: Epigenetic regulation of the expression of genes involved in steroid hormone biosynthesis and action. Steroids. 75:467–476. 2010. View Article : Google Scholar : PubMed/NCBI
11	Terao Y, Nishida J, Horiuchi S, Rong F, Ueoka Y, Matsuda T, Kato H, Furugen Y, Yoshida K, Kato K and Wake N: Sodium butyrate induces growth arrest and senescence-like phenotypes in gynecologic cancer cells. Int J Cancer. 94:257–267. 2001. View Article : Google Scholar : PubMed/NCBI
12	Jüttermann R, Li E and Jaenisch R: Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA. 91:11797–11801. 1994.
13	Zorn CS, Wojno KJ, McCabe MT, Kuefer R, Gschwend JE and Day ML: 5-Aza-2′-deoxycytidine delays androgen-independent disease and improves survival in the transgenic adenocarcinoma of the mouse prostate mouse model of prostate cancer. Clin Cancer Res. 13:2136–2143. 2007.
14	McCabe MT, Low JA, Daignault S, Imperiale MJ, Wojno KJ and Day ML: Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer. Cancer Res. 66:385–392. 2006. View Article : Google Scholar : PubMed/NCBI
15	Gravina GL, Marampon F, Di Staso M, Bonfili P, Vitturini A, Jannini EA, Pestell RG, Tombolini V and Festuccia C: 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors. Prostate. 70:1166–1178. 2010. View Article : Google Scholar : PubMed/NCBI
16	Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S and Chung LW: Derivation of androgen independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer. 57:406–412. 1994. View Article : Google Scholar : PubMed/NCBI
17	Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 47:936–942. 1987.PubMed/NCBI
18	Malikova J, Swaczynova J, Kolar Z and Strnad Z: Anticancer and antiproliferative activity of natural brassinosteroids. Phytochemistry. 69:418–426. 2008. View Article : Google Scholar : PubMed/NCBI
19	Tilley WD, Marcelli M and McPhaul MJ: Expression of the human androgen receptor gene utilizes a common promoter in diverse human tissues and cell lines. J Biol Chem. 265:13776–13781. 1990.PubMed/NCBI
20	Trtkova K, Paskova L, Matijescukova N, Strnad M and Kolar Z: Binding of AR to SMRT/N-CoR complex and its co-operation with PSA promoter in prostate cancer cells treated with natural histone deacetylase inhibitor NaB. Neoplasma. 57:406–414. 2010. View Article : Google Scholar : PubMed/NCBI
21	Jarrard DF, Kinoshita H, Shi Y, Sandefur C, Hoff D, Meisner LF, Chang C, Herman JG, Isaacs WB and Nassif N: Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res. 58:5310–5314. 1998.PubMed/NCBI
22	Nakayama T, Watanabe M, Suzuki H, Toyota M, Sekita N, Hirokawa Y, Mizokami A, Ito H, Yatani R and Shiraishi T: Epigenetic regulation of androgen receptor gene expression in human prostate cancers. Lab Invest. 80:1789–1796. 2000. View Article : Google Scholar : PubMed/NCBI
23	Kinoshita H, Shi Y, Sandefur C, Meisner LF, Chang C, Choon A, Reznikoff CR, Bova GS, Friedl A and Jarrard DF: Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. Cancer Res. 60:3623–3630. 2000.PubMed/NCBI
24	Mancini DN, Singh SM, Archer TK and Rodenhiser DI: Site-specific DNA methylation in the neurofibromatosis (NF1) promoter interferes with binding of CREB and SP1 transcription factors. Oncogene. 18:4108–4119. 1999. View Article : Google Scholar : PubMed/NCBI
25	Mishra DK, Chen Z, Wu Y, Sarkissyan M, Koeffler HP and Vadgama JV: Global methylation pattern of genes in androgen-sensitive and androgen-independent prostate cancer cells. Mol Cancer Ther. 9:33–45. 2010. View Article : Google Scholar : PubMed/NCBI
26	Cameron EE, Bachman KE, Myöhänen S, Herman JG and Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 21:103–107. 1999. View Article : Google Scholar : PubMed/NCBI
27	Dobosy JR and Selker EU: Emerging connections between DNA methylation and histone acetylation. Cell Mol Life Sci. 58:721–727. 2001. View Article : Google Scholar : PubMed/NCBI
28	Ahmed H: Promoter methylation in prostate cancer and its application for the early detection of prostate cancer using serum and urine samples. Biomark Cancer. 2:17–33. 2010. View Article : Google Scholar
29	Emanuele S, Lauricella M and Tesoriere G: Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review). Int J Oncol. 33:637–646. 2008.PubMed/NCBI
30	Marks PA and Xu WS: Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem. 107:600–608. 2009. View Article : Google Scholar : PubMed/NCBI
31	Zhu WG and Otterson GA: The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells (Review). Curr Med Chem Anticancer Agents. 3:187–199. 2003. View Article : Google Scholar : PubMed/NCBI
32	VanOosten RL, Earel JK Jr and Griffith TS: Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity. Apoptosis. 12:561–571. 2007. View Article : Google Scholar
33	Qiu J, Gao Z and Shima H: Growth of human prostate cancer cells is significantly suppressed in vitro with sodium butyrate through apoptosis. Oncol Rep. 27:160–167. 2012.PubMed/NCBI
34	Walton TJ, Li G, Seth R, McArdle SE, Bishop MC and Rees RC: DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines. Prostate. 68:210–222. 2008. View Article : Google Scholar : PubMed/NCBI
35	Tilley WD, Bentel JM, Aspinall JO, Hall RE and Horsfall DJ: Evidence for a novel mechanism of androgen resistance in the human prostate cancer cell line, PC-3. Steroids. 60:180–186. 1995. View Article : Google Scholar : PubMed/NCBI
36	Mizokami A and Chang C: Induction of translation by the 5′-untranslated region of human androgen receptor mRNA. J Biol Chem. 269:25655–25659. 1994.